Why Investors Misprice Regulatory Risk in Biotech

If regulatory risk is the dominant risk in biotech, why do so many investors price it badly? The answer lies less in the math than in psychology and incentives. Understanding why regulatory risk is consistently mispriced is the first step to pricing it better. This essay examines the pattern. It is educational and is not investment advice.

The science is visible, the regulatory risk is not

The most basic reason is salience. The science is concrete, exciting, and easy to discuss, while regulatory risk is abstract, technical, and dull. Investors gravitate toward what they can see and understand, so they over-weight the molecule and under-weight the path it must travel. This is a classic cognitive bias applied to biotech, and it leads systematically to overvaluing companies with compelling science and weak regulatory plans, a pattern connected to why FDA strategy determines valuation.

The base rates are uncomfortable, so they are ignored

The data on regulatory and clinical risk are stark: only a low double-digit percentage of drugs entering human testing reach approval, with sharp drop-offs at each phase (Wong, Siah, and Lo, 2019; Hay et al., 2014). These numbers are well known, yet investors routinely build theses that implicitly assume their company will beat them. People discount unwelcome base rates in favor of a compelling specific story, a tendency behavioral economists have documented across domains. In biotech this means the high probability of failure at regulatory gates is acknowledged in theory and ignored in practice.

Optimism is structurally rewarded

The incentives of the industry compound the bias. Founders must be optimistic to raise money, bankers are paid to sell deals, and even investors have incentives to deploy capital rather than sit out. Each link in the chain has reasons to emphasize upside and downplay regulatory risk. The result is an ecosystem that systematically tilts toward optimism, which shows up as mispriced regulatory risk in valuations, a dynamic visible across the cycles tracked by industry data (PitchBook and NVCA).

Regulatory expertise is scarce on the buy side

Pricing regulatory risk well requires understanding how regulators think, what endpoints they accept, and how trial designs fare in review. This expertise is genuinely scarce, and many investors lack it, so they default to evaluating the science, which they can assess, and treating the regulatory path as a black box. A risk that cannot be evaluated tends to be either ignored or crudely discounted, neither of which is accurate pricing. The investors who build or hire genuine regulatory expertise gain an edge precisely because it is rare, an edge tied to what makes a company investable.

The pattern Mispricing of regulatory risk is systematic and driven by salience, base-rate neglect, optimistic incentives, and scarce expertise.

How the mispricing shows up

The bias produces two recurring errors. Companies with exciting science and weak regulatory plans get overvalued, then fall hard when the regulatory reality surfaces. Companies with ordinary science and excellent regulatory strategy get overlooked, offering better risk-adjusted value than the market recognizes. Both are opportunities for an investor who prices regulatory risk accurately, and both are traps for one who does not. This is the practical payoff of correcting the bias.

How to price it better

Correcting the mispricing is conceptually simple and behaviorally hard. It means starting from the base rates rather than the story, reading the regulatory plan as carefully as the science, weighting endpoints and trial design heavily, and being willing to pass on dazzling science with a weak path while backing modest science with a strong one. It also means resisting the ecosystem's pull toward optimism. The framework for doing this is the subject of why biotech valuations ignore regulatory reality.

The takeaway

Regulatory risk is mispriced not because it is hard to see in the data but because it is psychologically and structurally inconvenient to act on. Investors who overcome that inconvenience, by grounding their judgment in base rates and regulatory literacy, gain a durable edge in a sector where most of the value turns on exactly the risk that most people underweight. For how this judgment is applied in practice, see the advisory practice and the related analysis in why biotech startups fail.

The contrarian opportunity in correct pricing

Systematic mispricing is, for the disciplined investor, a systematic opportunity. When the market consistently overvalues exciting science with weak regulatory paths and undervalues unglamorous companies with strong ones, an investor who prices regulatory risk accurately can position against both errors. This is genuinely contrarian, because it means passing on the deals that generate the most enthusiasm and backing the ones that generate the least, which is psychologically uncomfortable and professionally lonely. It also requires patience, because mispricing can persist for a long time before reality asserts itself, and being early is indistinguishable from being wrong until the gate is reached. But the structural nature of the bias means the opportunity is durable rather than fleeting. As long as salience, base-rate neglect, and optimistic incentives shape the market, regulatory risk will be mispriced, and the investors who do the harder analytical and emotional work of pricing it correctly will continue to find value where others see either too much or too little. This edge compounds over many decisions, which is why regulatory literacy is among the most valuable and least common skills on the buy side, a point connected to the discipline in why valuations ignore regulatory reality.

Why even experienced investors fall into it

It would be comforting to think that only inexperienced investors misprice regulatory risk, but the bias reaches the sophisticated too. Experience can even deepen it, because a string of successes can breed confidence that one can pick winners despite the base rates, and because professionals operate inside the same optimistic ecosystem and face the same pressure to deploy capital. The discipline required to consistently weight base rates over compelling stories runs against both human nature and professional incentives, which is why the mispricing persists across the experience spectrum rather than disappearing with seniority. The investors who avoid it tend to do so deliberately, by building base rates and regulatory analysis into their process as a structural check rather than relying on judgment in the moment, when enthusiasm is hardest to resist. This is the same kind of systematic discipline that distinguishes durable performance in any field where stories compete with probabilities.